Why the study?
Does intravenous BQ-123 improve myocardial perfusion in patients with posterior-wall STE-ACS undergoing primary PCI?
Population
57 patients with posterior-wall ST-elevation acute coronary syndrome (STE-ACS)
Comparison
Intravenous BQ-123 at 400 nmol/minute over 60… vs Placebo over 60 minutes, starting at the onset…
Design
RCT, randomly assigned, double-blind, placebo-controlled
Follow-up
6 months
Authors
Loading...
Supports adjunctive ETA blockade in primary PCI for STE-ACS; extends microvascular protection evidence.
Does intravenous BQ-123 improve myocardial perfusion in patients with posterior-wall STE-ACS undergoing primary PCI?
Administration of an ETA receptor blocker during primary PCI for STE-ACS improves tissue-level perfusion and LVEF, suggesting a protective effect on the microvasculature.
Adlbrecht et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: